L Kossmann

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Uncertainty concerning therapeutic targets has probably retarded the development of cognition-enhancing drugs. While enhancement of normal cognitive function may be a legitimate goal it is unlikely that drugs developed without a clear clinical indication will ever be approved by regulatory authorities. Normal aging as a target would also appear to be(More)
  • 1